Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

A compound of formula (I):

• wherein
• R1 is —ORa or —C(O)NRbRc;
• R2, R3, and R4 are each independently C1-3alkyl;
• R5 is selected from hydrogen, —CH2-cyclohexyl, benzyl, —CH2OH, and —C(O)OH;
• R6 is hydrogen or C1-3alkyl;
• R7 is selected from hydrogen, —C(O)R8, —C(O)NHR9, —C(S)NHR10, —S(O)2R11, and C1-6alkyl, optionally substituted with —C(O)NH2, —OH, —CN, —O(CH2)2OCH3, cyclohexyl, or phenyl, wherein cyclohexyl and phenyl are each optionally substituted with one or two halo;
• R8 is selected from phenyl, benzyl, C5-6cycloalkyl, furanyl, thiophenyl, and C1-6alkyl, wherein phenyl, benzyl, and C5-6cycloalkyl are optionally substituted with one or two halo or with —S(O)2NH2, and C1-6alkyl is optionally substituted with one or two substituents selected from —OH, —C(O)ORa, —C(O)NH2, —S(O)2CH3, phenyl, and —OCH2OCH3;
• R9 is selected from C1-6alkyl, phenyl, benzyl, and —CH2-cyclohexyl, wherein phenyl and benzyl are each optionally substituted with one or two substituents selected from halo, —OCH3, and —CF3;
• R10 is selected from C1-6alkyl, phenyl, and benzyl, wherein phenyl and benzyl are each optionally substituted with one or two halo;
• R11 is selected from C1-6alkyl, cyclohexyl, and phenyl, wherein phenyl is optionally substituted with —NHC(O)CH3 or with from 1 to 5 fluoro;
• Ra, Rb, and Rc are each independently hydrogen or C1-3alkyl;
• and
• n is 0 or 1;
• wherein the substituents at the chiral centers marked by asterisks are in the trans configuration;
• provided that when R1 is —ORa, then at least one of R5 and R7 is not hydrogen or C1-6alkyl;
• or a pharmaceutically-acceptable salt thereof.